Do you have any questions? (088) 2080369 - 2345622 Pharmacy_QAAU@pharm.aun.edu.eg
After reviewing the appeals submitted by students (for the Medicinal Plants course) and after reviewing the exam papers to verify the corrected questions and the totaling of marks, it was determined that no student was entitled to any additional marks.
The students’ grievances have been reviewed, and the results are as follows:
No. | Name | Grievance | Result of Grievance |
1 | Tamer Alaa El-Din Maher | Functional group | No additional marks granted after review |
2 | Rana Essam Ahmed | Functional group | No additional marks granted after review |
3 | Habiba Ehab Haggagy | Functional group | No additional marks granted after review |
4 | Mohamed Abdelhamid Ali | Functional group | Granted half a mark after review; total becomes 9 marks |
5 | Saberien Hassan Hosny | Functional group | No additional marks granted after review |
6 | Mohamed Yassin Sediq | Functional group | No additional marks granted after review |
With best wishes for success.
God willing, the meeting of the Pharmaceutics Department Board of the Faculty of Pharmacy No. (545) will be held on Monday, December 1, 2025, at 10:00 A.M
in the department board on the third floor under the chairmanship of the Faculty to discuss the topics that we will inform you later.
The midterm exam for the Matrouh (Pharmacognosy -1) course for Clinical Pharmacy and PharmD students will now be held on Thursday, December 4, 2025, at 12:30 PM in the third-floor labs of the Pharmacognosy Department.
The practical exam for the Matrouh (Pharmacognosy -1) course for Clinical Pharmacy and Pharm-D students has been rescheduled to Monday, December 15, 2025, from 10:00 AM to 11:30 AM in the third-floor labs of the Pharmacognosy Department.
Important Notice
The exam will not be repeated for any student who is absent for any reason.
The practical exam for the Matrouh (Pharmacognosy -1) course for students of the private university has been rescheduled to Monday, 15/12/2025, from 10:00 AM to 11:30 AM in the fourth-floor labs of the Pharmacognosy Department.
Important Notice
The exam will not be repeated for any student who is absent for any reason.
After reviewing the re-evaluation requests submitted by First-Year Pharm-D students and Clinical Pharmacy students for the Medicinal Plants course and after rechecking the exam papers to ensure all questions were correctly graded and all marks were accurately summed,
it has been determined that no student is eligible for any additional marks.
The midterm exam for Clinical Pharmacy Program students and Pharm-D students in the offered (Pharmacognosy -1) course will be held on Monday, 1 December 2025, at 11:00 AM in the Lecture Hall (3rd Floor), Department of Pharmacognosy.
Wishing you all the best of luck.
Abstract: Skin cancer requires effective treatment due to its high incidence and mortality. Curcumin’s anti-tumor effects are restricted by its lower bioavailability, dose dependency, and poor skin permeability. Hybrid curcumin molecules with spinal metalferrite and biogenicsilver/silver chloride (Ag/AgCl) nanoparticles could be a promising approach for the efficient delivery of curcumin to cancer cells. AgClM0.5Fe2O4 and AgClM0.5Fe2O4/curcumin hybrid nanocomposites weresynthesized via chemical co-precipita tion and wet impregnation techniques. Furthermore, they were characterized using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), energy-dispersive X-ray spectroscopy (EDX), transmission electron microscopy (TEM), dynamic light scattering (DLS), and vibrating sample magnetometry (VSM). The cytotoxicity, apoptosis, and cell cycling of hybrid nanocomposites wereevaluated onhuman epidermoid skin carcinoma (A-431) and human skin fibro blast (HSF) cell lines. Results showed successful curcumin loading, high physical stability, and enhanced magnetic properties of the hybridnanocomposites.Cytotoxicityassays revealed selective toxicity against both A-431 and HSF cell lines with IC₅₀ values of 26.83 and 34.83µg/ml for AgClCd0.5Fe2O4 and AgClMg0.5Fe2O4/curcumin, respectively. AgClCd0.5Fe2O4/curcumin exhibited greater apoptosis induc tion (14.52% late apoptosis, 8.53% necrosis) compared to AgClMg0.5Fe2O4/curcumin (10.20% late apoptosis, 6.07% necrosis). In addition, cell cycle analysis showed a signifi cant increase in the sub-G1 phase, with AgClCd0.5Fe2O4/cur cumin demonstrating superior efficacy. In conclusion, hybrid nanocomposites triggered cell cycle arrest and apop tosis, with AgClCd0.5Fe₂O₄/curcumin being the most potent. Their lower toxicity compared to doxorubicin suggests their potential application in skin cancer treatment.
To improve medication adherence in patients with chronic diseases by developing a tablet formulation containing a combination of metformin, atorvastatin, aspirin, and enalapril maleate. Significance: Effectively managing chronic diseases often requires multiple medications, which can result in low patient adherence and suboptimal therapeutic outcomes. Developing a combination tablet is an effective modality to address this issue.
To test the patient perception, an online survey was distributed patients with chronic diseases. Based on the survey results, combination tablets were prepared by direct compression using a multifunctional excipient (PROSOLV® EASYtab). The compatibility between the drugs and excipients was studied using differential scanning calorimetry (DSC) and Fourier-transform infrared (FT-IR) spectroscopy. The tablets were evaluated for weight uniformity, friability, hardness, thickness, diameter, disintegration time, uniformity of drug content, and in vitro drug release.
Most participants reported issues with non-adherence, but expressed a strong positive perception of combination tablets, particularly regarding their effectiveness in improving their condition. DSC and FT-IR studies confirmed the compatibility of the investigated drugs with each other and the used excipient. The tablets fulfilled the European Pharmacopeia 2014 specifications for the tested parameters. The release of all four drugs was fast and a cumulative percent drug release of approximately 50–85% was observed after 15 min.
These findings highlight the significant potential of the combination tablets as a single-dose delivery system, allowing the simultaneous administration of multiple medications for patients with chronic diseases, thereby enabling more effective and streamlined management.
